✦ LIBER ✦

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study

✍ Scribed by TrÃ©dan, Olivier; Treilleux, Isabelle; Wang, Qing; Gane, Nicolas; Pissaloux, Daniel; Bonnin, Nathalie; Petit, Thierry; Cretin, Jacques; Bonichon-Lamichhane, Nathalie; Priou, Frank; Lavau-Denes, Sandrine; Mari, VÃ©ronique; Freyer, Gilles; Lebrun, Daniela; Alexandre, JÃ©rÃ´me; Ray-Coquard, Isabelle

Book ID: 120502270
Publisher: Springer-Verlag
Year: 2012
Tongue: English
Weight: 260 KB
Volume: 8
Category: Article
ISSN: 1776-2596
DOI: 10.1007/s11523-012-0242-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predicting everolimus/letrozole treatmen

Predicting everolimus/letrozole treatment efficacy in patients with advanced or recurrent endometrial cancer: A biomarker study

✍ Jiang, Y.; Slomovitz, B.M.; Zhang, Q.; Amin, Y.; Broaddus, R.; Coleman, R.L.; Lu 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Treatment of advanced or recurrent endom

Treatment of advanced or recurrent endometrial carcinoma with medroxyprogesterone acetate (MPA): A gynecologic oncology group study

✍ T. Thigpen; J. Blessing; P. DiSaia; C. Ehrlich 📂 Article 📅 1985 🏛 Elsevier Science 🌐 English ⚖ 96 KB

A Phase II Trial of Topotecan in Patient

A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; Steven E. Waggoner 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Early alpha-fetoprotein response predict

Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma

✍ Yu-Yun Shao; Zhong-Zhe Lin; Chiun Hsu; Ying-Chun Shen; Chih-Hung Hsu; Ann-Lii Ch 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB 👁 2 views

A phase 2 study of the oral mammalian ta

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

✍ Brian M. Slomovitz; Karen H. Lu; Taren Johnston; Robert L. Coleman; Mark Munsell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are the most common mutations in endometrial carcinoma (EC). Loss of PTEN or activation of PIK3CA results in cons

Phase II study of carboplatin in patient

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group

✍ F.H van Wijk; C Lhommé; G Bolis; V Scotto di Palumbo; S Tumolo; M Nooij; C.F de 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 139 KB